Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System AtrophyGlobeNewsWire • 11/08/23
Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian DisorderGlobeNewsWire • 08/31/23
Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson's and Alzheimer'sGlobeNewsWire • 08/23/23
Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson's Disease and Movement DisordersGlobeNewsWire • 08/22/23
Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive RefundGlobeNewsWire • 08/15/23
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as PlannedGlobeNewsWire • 07/26/23
Alterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023GlobeNewsWire • 06/21/23
Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian DisorderGlobeNewsWire • 05/30/23
Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023GlobeNewsWire • 05/19/23
Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System AtrophyGlobeNewsWire • 05/10/23
Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of NeurologyGlobeNewsWire • 04/26/23
Alterity Therapeutics Enrolls First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System AtrophyGlobeNewsWire • 04/04/23
Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System AtrophyGlobeNewsWire • 03/16/23
Alterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer's DiseaseGlobeNewsWire • 03/14/23
Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System AtrophyGlobeNewsWire • 03/08/23
Alterity Therapeutics Receives Regulatory Authorization in France and Austria to Proceed with ATH434 Phase 2 Clinical TrialGlobeNewsWire • 02/16/23
Alterity's ATH434 Prevents Loss of Brain Cells in Parkinson's Disease Animal ModelGlobeNewsWire • 01/30/23
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System AtrophyGlobeNewsWire • 01/25/23
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System AtrophyPRNewsWire • 01/09/23
Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation ForumPRNewsWire • 01/03/23